Synthetic thymosin beta-4 fragment peptide
Thymosin Beta-4 Fragment
A regenerative peptide discussed for soft-tissue recovery; human clinical evidence remains primarily preclinical.
- Evidence:
- Preclinical evidence primarily
- Status:
- Research-stage
- Reviewed:
- 2026-08-03
Also known as: Thymosin Beta-4 Fragment, TB4
What is Thymosin Beta-4 Fragment?
A regenerative peptide discussed for soft-tissue recovery; human clinical evidence remains primarily preclinical.
This profile is educational. It organizes publicly discussed research context for Thymosin Beta-4 Fragment and related naming aliases — it is not a treatment guide.
Proposed mechanism
Actin sequestration and cell migration promotion; angiogenesis and anti-inflammatory signaling via thymosin beta-4 pathways.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Preclinical evidence primarily
Preclinical evidence grade: Early-stage human research
TB-500 derives from thymosin beta-4, which has legitimate pharmaceutical development history (e.g., regeneRx programs). The fragment sold in research markets lacks equivalent clinical validation. Preclinical models show tissue remodeling effects. Human evidence is insufficient for strong conclusions.
Key uncertainties
- Fragment vs full TB4 activity
- Human efficacy for injury recovery
Research areas being studied
- Soft tissue repair
- Wound healing
- Cardiac repair research
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Poorly characterized in humans
Additional risks & considerations
- Evidence gaps
- Unregulated products
- WADA prohibited
Regulatory status
Research-stage
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is Thymosin Beta-4 Fragment?
A regenerative peptide discussed for soft-tissue recovery; human clinical evidence remains primarily preclinical.
How does Thymosin Beta-4 Fragment work (proposed mechanism)?
Actin sequestration and cell migration promotion; angiogenesis and anti-inflammatory signaling via thymosin beta-4 pathways.
What is Thymosin Beta-4 Fragment being researched for?
Thymosin Beta-4 Fragment has been discussed in research contexts including: Soft tissue repair, Wound healing, Cardiac repair research.
What does current evidence say about Thymosin Beta-4 Fragment?
Preclinical evidence primarily. TB-500 derives from thymosin beta-4, which has legitimate pharmaceutical development history (e.g., regeneRx programs). The fragment sold in research markets lacks equivalent clinical validation. Preclinical models show tissue remodeling effects. Human evidence is insufficient for strong conclusions.
What safety considerations are noted for Thymosin Beta-4 Fragment?
Reported or discussed considerations include: Poorly characterized in humans; Evidence gaps; Unregulated products; WADA prohibited. This is educational information, not medical advice.
References & sources
- Goldstein AL et al. (2005). Thymosin beta4: actin-sequestering protein with diverse biological activities — Ann NY Acad Sci. Evidence type: review.
Prefer interactive tools? Open the PepGuide library entry for Thymosin Beta-4 Fragment or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.